Good morning. Here is Matt Lowdon‘s Monday update that focuses on deals and acquisitions across Newton Colmore‘s core markets. Headlines include GLP-1s, neurotechnology, small molecule therapeutics and more. Congratulations to everyone involved.
🔔 Novo Nordisk makes bombshell $6.5B counteroffer to Pfizer‘s acquisition of obesity biotech Metsera
🔔 CoMind raises $102.5M to develop non-invasive bedside brain monitor
🔔 In one of the biggest healthcare acquisitions of its kind this year, medtech diagnostics specialist Hologic, Inc. will go private following its sale to Blackstone and TPG in a deal valued at more than $18.3 billion.
🔔 Ottobock has expanded its investment in ONWARD Medical, a European medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury.
🔔 California-based biotech Electra Therapeutics Inc has secured US$183m in Series C financing.
🔔 US-based biotech company, Kure Cells secured USD 10 million in a series A funding round led by Wa’ed Ventures.
🔔 Hemab Therapeutics A/S has completed an oversubscribed US$157m Series C financing round led by Sofinnova Partners to accelarate and expand its pipeline in bleeding disorders and thrombosis treatments.
🔔 Italian biotech AAVantgarde adds $143M series B to fund retinal disease gene therapy trials
🔔 Boehringer Ingelheim returns to Kyowa Kirin International plc. with €640M pact for preclinical autoimmune molecule
🔔 AbbVie, Regeneron and Sanofi help fund $80M series A round for Tregs specialist Zag Bio
🔔 GSK pens $745M deal for Empirico’s phase 1 drug that hits sweet spots of COPD, oligonucleotides
🔔 Pharma giant Ipsen will pay US$1bn to acquire French immuno-oncology firm ImCheck Therapeutics SAS. The deal includes US$350m upfront and up to US$650m in milestone payments
🔔 MapLight Therapeutics, Inc. is heading to the Nasdaq this morning via a $250 million IPO the biotech will use to advance its challenger to Bristol Myers Squibb’s schizophrenia med Cobenfy.
🔔 Thermo Fisher Scientific Fisher adds clinical trial tech outfit Clario to goodie bag in $9B deal